Dienstmann R - Search Results

1

Precision Therapy in RAS Mutant Colorectal Cancer.

Dienstmann R, Connor K, Byrne AT; COLOSSUS Consortium. Dienstmann R, et al. Gastroenterology. 2020 Mar;158(4):806-811. doi: 10.1053/j.gastro.2019.12.051. Epub 2020 Jan 21. Gastroenterology. 2020. PMID: 31972237 No abstract available.

2

Challenges and opportunities in building a health economic framework for personalized medicine in oncology.

Aguiar PN, Matsas S, Dienstmann R, Ferreira CG. Aguiar PN, et al. Among authors: dienstmann r. Per Med. 2023 Sep;20(5):453-460. doi: 10.2217/pme-2022-0008. Epub 2023 Aug 21. Per Med. 2023. PMID: 37602420 Review.

3

Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil.

Resende CAA, Fernandes Cruz HM, Costa E Silva M, Paes RD, Dienstmann R, Barrios CHE, Goncalves AC, Cascelli FGA, Souto AKBA, Oliveira LC, Reinert T, Andrade DAP, Passos MP, Millen EC, Zerwes F, Moraes PL, Ferrari BL, Mano MS. Resende CAA, et al. Among authors: dienstmann r. JCO Glob Oncol. 2022 Nov;8:e2200289. doi: 10.1200/GO.22.00289. JCO Glob Oncol. 2022. PMID: 36351212 Free PMC article.

4

BRAF as a target for cancer therapy.

Dienstmann R, Tabernero J. Dienstmann R, et al. Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. doi: 10.2174/187152011795347469. Anticancer Agents Med Chem. 2011. PMID: 21426297 Review.

5

Development of molecular biomarkers in individualized treatment of colorectal cancer.

De Mattos-Arruda L, Dienstmann R, Tabernero J. De Mattos-Arruda L, et al. Among authors: dienstmann r. Clin Colorectal Cancer. 2011 Dec;10(4):279-89. doi: 10.1016/j.clcc.2011.03.030. Epub 2011 May 12. Clin Colorectal Cancer. 2011. PMID: 21729679 Review.

6

Panitumumab: a summary of clinical development in colorectal cancer and future directions.

Argiles G, Dienstmann R, Elez E, Tabernero J. Argiles G, et al. Among authors: dienstmann r. Future Oncol. 2012 Apr;8(4):373-89. doi: 10.2217/fon.12.20. Future Oncol. 2012. PMID: 22515440 Review.

7

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J. Dienstmann R, et al. Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21. Mol Cancer Ther. 2012. PMID: 22723336

8

Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer.

Dienstmann R, Salazar R, Tabernero J. Dienstmann R, et al. Am Soc Clin Oncol Educ Book. 2015:e149-56. doi: 10.14694/EdBook_AM.2015.35.e149. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993166 Free article. Review.

9

Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.

Dienstmann R, Tabernero J. Dienstmann R, et al. Cancer J. 2016 May-Jun;22(3):149-55. doi: 10.1097/PPO.0000000000000191. Cancer J. 2016. PMID: 27341591 Review.

10

Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer.

Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Dienstmann R, et al. Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4. Nat Rev Cancer. 2017. PMID: 28050011 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

165 results

Search Page